Isavuconazole: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
AWMSG (Wales), CIPM (Spain) and CONITEC (Brazil), among others, recommended or restricted isavuconazole, while AOTMIT (Poland) did not recommend it.
Where isavuconazole met resistance it was usually narrowed rather than refused: 4 of 9 decisive outcomes were recommendations with restrictions, against 1 outright refusal.
Assessment has run over 9 years, from 11 Apr 2016 at SMC (Scotland) to 24 Apr 2025 at CIPM (Spain).
No assessment is on file from HAS (France), PBAC (Australia) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
SMC (Scotland) was first to assess isavuconazole, on 11 Apr 2016; CIPM (Spain) did not open a file until 24 Apr 2025 — an unusually long tail of 9 years between the earliest and latest system to look at it.
The record arrives in waves: 4 separate years each carry two or more decisions, spread across 5 years in total.
Restriction is doing real work here: 4 of 9 decisive outcomes narrowed isavuconazole to a subgroup rather than accepting or refusing it outright, at G-BA (Germany) and TLV (Sweden).
2 of the 8 agencies here assessed isavuconazole more than once, G-BA (Germany) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
8 of the 18 agencies in this archive hold a record for isavuconazole.
The full ledger for isavuconazole reads 4 recommended, 4 restricted, 1 not recommended and 1 other, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| CIPM (Spain) | 24 Apr 2025 | Indicaciones terapéuticas autorizadas: Cresemba cápsulas duras está indicado en adultos y pacientes pediátricos a partir… | financed by the SNS · art. 92 a, c | source |
| G-BA (Germany) | 20 Mar 2025 | Cresemba — benefit assessment §35a | added benefit: non-quantifiable (hint) | source |
| CONITEC (Brazil) | 28 Jul 2022 | Tratamento de pessoas diagnosticadas com todas as formas de mucormicose. | incorporated into SUS | source |
| AOTMIT (Poland) | 25 Mar 2022 | Cresemba reimbursement recommendation | not recommended | source |
| ZIN (Netherlands) | 31 Jul 2018 | GVS-advies isavuconazol (Cresemba®) bij volwassenen voor de behandeling van invasieve aspergillose en mucormycose | advice published (GVS) | source |
6 further decisions for isavuconazole, across 5 agencies, are not shown here. They link to 5 further source documents.
Related molecules
- posaconazole — same ATC class J02A — Antimycotics
- voriconazole — same ATC class J02A — Antimycotics
- caspofungin — same ATC class J02A — Antimycotics
- anidulafungin — same ATC class J02A — Antimycotics
- micafungin — same ATC class J02A — Antimycotics
- osimertinib — also decided by CIPM in 2025Q2
Coverage: 11 decisions for isavuconazole from 8 agencies, 2016 to 2025. Data to 7 Sep 2026. ATC class J02A — Antimycotics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.